• >
  • >
  • >
  • >
  • >
Google > Case Studies > Google Cloud Launches AI-powered Solutions to Safely Accelerate Drug Discovery and Precision Medicine

Google Cloud Launches AI-powered Solutions to Safely Accelerate Drug Discovery and Precision Medicine

Google Logo
Customer Company Size
Large Corporate
Country
  • United States
Product
  • Target and Lead Identification Suite
  • Multiomics Suite
  • Vertex AI
  • Google Cloud Storage
  • BigQuery
Tech Stack
  • AlphaFold2
  • NVIDIA's Parabricks
  • Google's DeepVariant
  • Compute Engine
  • Looker
Implementation Scale
  • Enterprise-wide Deployment
Impact Metrics
  • Digital Expertise
  • Innovation Output
  • Productivity Improvements
Technology Category
  • Analytics & Modeling - Machine Learning
  • Analytics & Modeling - Predictive Analytics
  • Platform as a Service (PaaS) - Data Management Platforms
Applicable Industries
  • Life Sciences
  • Pharmaceuticals
  • Healthcare & Hospitals
Applicable Functions
  • Product Research & Development
  • Quality Assurance
Use Cases
  • Digital Twin
  • Predictive Maintenance
  • Remote Asset Management
Services
  • Cloud Planning, Design & Implementation Services
  • Data Science Services
  • System Integration
About The Customer
Cerevel, Colossal Biosciences, and Pfizer are prominent players in the pharmaceutical and biotech industries, each with a unique focus on advancing drug discovery and precision medicine. Cerevel is known for its work in neuroscience, aiming to develop treatments for neurological and psychiatric disorders. Colossal Biosciences, on the other hand, is a cutting-edge biotech company focused on de-extinction and genetic engineering, leveraging advanced genomic technologies to bring back extinct species and enhance biodiversity. Pfizer, a global pharmaceutical giant, is renowned for its extensive portfolio of medicines and vaccines, with a strong emphasis on research and development to address a wide range of health challenges. These companies are at the forefront of innovation, utilizing AI-powered solutions from Google Cloud to accelerate drug discovery processes and enhance precision medicine capabilities. By adopting these advanced technologies, they aim to streamline research, reduce development timelines, and ultimately bring novel therapeutics to market more efficiently.
The Challenge
Speeding up target and lead identification is critical for the race to drug discovery. Currently, developing a new drug from an original idea to the launch of a finished product is a complex process that can take 12–15 years and cost more than $1 billion, according to the British Journal of Pharmacology. In addition, identifying a biological target involved in the disease that is viable for drug intervention can take up to 12 months (NIH, National Center for Biotechnology Information). At the same time, most companies use X-ray crystallography and nuclear magnetic resonance (NMR) to determine protein 3D structures, but this has a high ratio of failures. Finally, once the drug discovery process is underway, it's not easy to scale supporting technology up or down based on demand.
The Solution
Google Cloud's Target and Lead Identification Suite enables biopharma companies to bring therapeutics to market faster by enabling more efficient in silico drug design. Its target identification will help companies quickly predict antibody structures, assess the structure and function of amino acid mutagenesis, and accelerate de novo protein design. This solution also enables lead optimization that can be used to discover novel, high-quality candidates at low cost for Quantitative Structure Activity Relationship (QSAR) studies or for Free Energy Perturbation (FEP) calculations. The Target and Lead Identification Suite includes data ingestion, target identification using AlphaFold2 and Vertex AI pipelines, and lead identification with cost-effective high-performance computing resources. The Multiomics Suite advances precision medicine care by transforming multiomics data into insights to advance scientific discoveries. Organizations can use this solution to streamline and accelerate analysis of genomic data, design clinical genomics, accelerate personalized medicine, and interpret genomic data to unlock new discoveries. The solution also provides structure and processes for researchers and data scientists to collaborate, saving time on developing net new paths, algorithms, or methods. What sets the Multiomics Suite apart is that it is cloud agnostic, allowing organizations to leverage existing investments in multiomics in a simplified environment. It also offers complete traceability through Vertex AI, so customers can organize millions of artifacts in their cloud environments.
Operational Impact
  • Google Cloud's Target and Lead Identification Suite enables more efficient in silico drug design, helping companies quickly predict antibody structures and accelerate de novo protein design.
  • The Multiomics Suite advances precision medicine care by transforming multiomics data into insights, streamlining and accelerating analysis of genomic data, and designing clinical genomics.
  • The solutions provide structure and processes for researchers and data scientists to collaborate, saving time on developing new paths, algorithms, or methods.
Quantitative Benefit
  • Developing a new drug can take 12–15 years and cost more than $1 billion.
  • Identifying a biological target for drug intervention can take up to 12 months.
  • Genomic data volume doubles every 7-12 months.

Case Study missing?

Start adding your own!

Register with your work email and create a new case study profile for your business.

Add New Record

Related Case Studies.

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that AGP may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from AGP.
Submit

Thank you for your message!
We will contact you soon.